Amgen's Blincyto (blinatumumab) was the first US FDA-approved bi-specific antibody and now the biotechnology giant may spend nearly $1.75bn on bi-specifics developed with Xencor Inc.'s XmAb platform for monoclonal antibodies that bind to two separate targets.
Thousand Oaks, California-based Amgen will pay Xencor $45m up front and up to $1.7bn in clinical, regulatory and sales milestone...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

